Immunological considerations for COVID-19 vaccine strategies

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · see citing works

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · see citing works

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

COVID-19: consider cytokine storm syndromes and immunosuppression

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664 · see citing works

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works

The trinity of COVID-19: immunity, inflammation and intervention

Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360 · see citing works

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · see citing works

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222 · see citing works

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595 · see citing works

SARS and MERS: recent insights into emerging coronaviruses

de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe

Flaxman, S., Mishra, S., Gandy, A., Unwin, H., Mellan, T., Coupland, H., Whittaker, C., Zhu, H., Berah, T., Eaton, J., et al. (2020) · Nature · doi:10.1038/s41586-020-2405-7 · Cited by 3,072 · see citing works

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045 · see citing works

Antibody responses to SARS-CoV-2 in patients with COVID-19

Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876 · see citing works

Defining trained immunity and its role in health and disease

Netea, M. G., Domínguez-Andrés, J., Barreiro, L. B., Chavakis, T., Divangahi, M., Fuchs, E., Joosten, L. A. B., van der Meer, J. W. M., Mhlanga, M. M., Mulder, W. J. M., et al. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0285-6 · Cited by 2,690 · see citing works

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686 · see citing works

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614 · see citing works

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607 · see citing works

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501 · see citing works

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472 · see citing works

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · see citing works

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Zou, X., Chen, K., Zou, J., Han, P., Hao, J., & Han, Z. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0754-0 · Cited by 2,287 · see citing works

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,278 · see citing works

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2

Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,908 · see citing works

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887 · see citing works

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885 · see citing works

Multiorgan and Renal Tropism of SARS-CoV-2

Puelles, V. G., Lütgehetmann, M., Lindenmeyer, M. T., Sperhake, J. P., Wong, M. N., Allweiss, L., Chilla, S., Heinemann, A., Wanner, N., Liu, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2011400 · Cited by 1,775 · see citing works

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

Sanche, S., Lin, Y. T., Xu, C., Romero-Severson, E., Hengartner, N., & Ke, R. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200282 · Cited by 1,619 · see citing works

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., et al. (2020) · Science · doi:10.1126/science.abb7498 · Cited by 1,614 · see citing works

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works

Developing Covid-19 Vaccines at Pandemic Speed

Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557 · see citing works

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537 · see citing works

Site-specific glycan analysis of the SARS-CoV-2 spike

Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., & Crispin, M. (2020) · Science · doi:10.1126/science.abb9983 · Cited by 1,507 · see citing works

Development of an inactivated vaccine candidate for SARS-CoV-2

Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434 · see citing works

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works

Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?

Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E. H., Cohen, A. A., Witkowski, J. M., & Franceschi, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01960 · Cited by 1,364 · see citing works

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2598-9 · Cited by 1,310 · see citing works

Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients

Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., Sun, R., Tian, Z., Xu, X., & Wei, H. (2020) · National Science Review · doi:10.1093/nsr/nwaa041 · Cited by 1,295 · see citing works

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225 · see citing works

BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis

Kaufmann, E., Sanz, J., Dunn, J. L., Khan, N., Mendonça, L. E., Pacis, A., Tzelepis, F., Pernet, E., Dumaine, A., Grenier, J.-C., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.031 · Cited by 1,191 · see citing works

BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity

Arts, R. J. W., Moorlag, S. J. C. F. M., Novakovic, B., Li, Y., Wang, S.-Y., Oosting, M., Kumar, V., Xavier, R. J., Wijmenga, C., Joosten, L. A. B., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.010 · Cited by 1,190 · see citing works

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126 · see citing works

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., et al. (2020) · Science · doi:10.1126/science.abd3871 · Cited by 1,120 · see citing works

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2020) · Viruses · doi:10.3390/v12030254 · Cited by 1,116 · see citing works

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Ni, L., Ye, F., Cheng, M., Yu, F., Deng, Y., Zhao, H. J., Peng, W., Ge, J., Gou, M., Li, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.023 · Cited by 1,069 · see citing works

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · see citing works

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914 · see citing works

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M. M., Oude Munnink, B. B., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N. M. A., et al. (2020) · Science · doi:10.1126/science.abb7314 · Cited by 901 · see citing works

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884 · see citing works

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847 · see citing works

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830 · see citing works

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

Restrepo, A. M. H., Longini, I. M., Egger, M., Dean, N. E., Edmunds, W. J., Camacho, A., Carroll, M. W., Doumbia, M. M., Draguez, B., Duraffour, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61117-5 · Cited by 794 · see citing works

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.008 · Cited by 748 · see citing works

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Brumbaugh, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2324-7 · Cited by 720 · see citing works

Location, location, location: Tissue resident memory T cells in mice and humans

Szabo, P. A., Miron, M., & Farber, D. L. (2019) · Science Immunology · doi:10.1126/sciimmunol.aas9673 · Cited by 651 · see citing works

Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers

Chou, R., Dana, T., Buckley, D., Selph, S., Fu, R., & Totten, A. M. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1632 · Cited by 645 · see citing works

History of vaccination

Plotkin, S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400472111 · Cited by 642 · see citing works

Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses

Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642 · see citing works

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2

Liu, W., Liu, L., Kou, G., Zheng, Y., Ding, Y., Ni, W., Wang, Q., Tan, L., Wu, W., Tang, S., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00461-20 · Cited by 630 · see citing works

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines

Giudice, G. D., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 617 · see citing works

Immunogenicity of a DNA vaccine candidate for COVID-19

Smith, T. R. F., Patel, A., Ramos, S., Elwood, D., Zhu, X., Yan, J., Gary, E. N., Walker, S. N., Schultheis, K., Purwar, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16505-0 · Cited by 601 · see citing works

The time course of the immune response to experimental coronavirus infection of man

Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598 · see citing works

Going viral with cancer immunotherapy

Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3770 · Cited by 584 · see citing works

New Vaccine Technologies to Combat Outbreak Situations

Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579 · see citing works

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Tseng, C.-T. K., Sbrana, E., Iwata‐Yoshikawa, N., Newman, P. C., Garron, T. M., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 555 · see citing works

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530 · see citing works

Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity

Yao, Y., Jeyanathan, M., Haddadi, S., Barra, N. G., Vaseghi‐Shanjani, M., Damjanovic, D., Lai, R., Afkhami, S., Chen, Y., Dvorkin‐Gheva, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.042 · Cited by 520 · see citing works

BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment

Cirovic, B., de Bree, L. C. J., Groh, L., Blok, B. A., Chan, J., van der Velden, W. J. F. M., Bremmers, M. E. J., van Crevel, R., Händler, K., Picelli, S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.014 · Cited by 510 · see citing works

BCG-induced trained immunity: can it offer protection against COVID-19?

O'Neill, L. A. J., & Netea, M. G. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0337-y · Cited by 501 · see citing works

The promise of mRNA vaccines: a biotech and industrial perspective

Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498 · see citing works

Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses

Zhao, J., Zhao, J., Mangalam, A. K., Channappanavar, R., Fett, C., Meyerholz, D. K., Agnihothram, S., Baric, R. S., David, C. S., & Perlman, S. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.006 · Cited by 496 · see citing works

Non-specific effects of BCG vaccine on viral infections

Moorlag, S. J. C. F. M., Arts, R. J. W., van Crevel, R., & Netea, M. G. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.020 · Cited by 479 · see citing works

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477 · see citing works

Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection

Netea, M. G., Giamarellos‐Bourboulis, E. J., Domínguez‐Andrés, J., Curtis, N. C., van Crevel, R., van de Veerdonk, F. L., & Bonten, M. J. M. (2020) · Cell · doi:10.1016/j.cell.2020.04.042 · Cited by 462 · see citing works

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

McKay, P. F., Hu, K., Blakney, A. K., Samnuan, K., Brown, J. C., Penn, R., Zhou, J., Bouton, C. R., Rogers, P., Polra, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17409-9 · Cited by 462 · see citing works

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 461 · see citing works

DNA Vaccines—How Far From Clinical Use?

Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457 · see citing works

Duration of Antibody Responses after Severe Acute Respiratory Syndrome

Wu, L.-P., Wang, N.-C., Chang, Y.-H., Tian, X.-Y., Na, D.-Y., Zhang, L.-Y., Zheng, L., Lan, T., Wang, L.-F., & Liang, G.-D. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1310.070576 · Cited by 426 · see citing works

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and <i>Toxoplasma gondii</i> challenges with a single dose

Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414 · see citing works

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infectionPreprint

Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K., Hemmings, O., O'Bryne, A., Kouphou, N., Pickering, S., Rui, G.-L. P., et al. (2020) · medRxiv · doi:10.1101/2020.07.09.20148429 · Cited by 411 · see citing works

Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies

Schulert, G. S., & Grom, A. A. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061813-012806 · Cited by 401 · see citing works

Lung niches for the generation and maintenance of tissue-resident memory T cells

Turner, D., Bickham, K. L., Thome, J. J. C., Kim, C. Y., D’Ovidio, F., Wherry, E. J., & Färber, D. L. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.67 · Cited by 399 · see citing works

New insights into the immunopathology and control of dengue virus infection

Screaton, G. R., Mongkolsapaya, J., Yacoub, S., & Roberts, C. (2015) · Nature reviews. Immunology · doi:10.1038/nri3916 · Cited by 398 · see citing works

Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want

HogenEsch, H., O’Hagan, D. T., & Fox, C. B. (2018) · npj Vaccines · doi:10.1038/s41541-018-0089-x · Cited by 393 · see citing works

Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

Gray, G., Allen, M., Moodie, Z., Churchyard, G., Bekker, L., Nchabeleng, M., Mlisana, K. P., Metch, B. J., de Bruyn, G., Latka, M. H., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70098-6 · Cited by 388 · see citing works

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

Buchholz, U. J., Bukreyev, A. A., Yang, L., Lamirande, E. W., Murphy, B. R., Subbarao, K., & Collins, P. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403492101 · Cited by 385 · see citing works

Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery

Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367 · see citing works

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

Laczko, D. I., Hogan, M. J., Toulmin, S. A., Hicks, P. D., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.019 · Cited by 366 · see citing works

Viruses as vaccine vectors for infectious diseases and cancer

Draper, S. J., & Heeney, J. L. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2240 · Cited by 352 · see citing works

Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets

Weingartl, H. M., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G. A., Jones, S. E., Proulx, R., Deschambault, Y., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12672-12676.2004 · Cited by 344 · see citing works

T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice

Zhao, J., Zhao, J., & Perlman, S. (2010) · Journal of Virology · doi:10.1128/jvi.01049-10 · Cited by 340 · see citing works

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

Yu, H.-Q., Sun, B.-Q., Fang, Z., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01526-2020 · Cited by 326 · see citing works

Lessons for COVID-19 immunity from other coronavirus infections

Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317 · see citing works

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

Padoan, A., Sciacovelli, L., Basso, D., Negrini, D., Zuin, S., Cosma, C., Faggian, D., Matricardi, P. M., & Plebani, M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.04.026 · Cited by 310 · see citing works

Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections

Remy, K. E., Mazer, M. B., Striker, D. A., Ellebedy, A. H., Walton, A. H., Unsinger, J., Blood, T. M., Mudd, P. A., Yi, D. J., Mannion, D. A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140329 · Cited by 309 · see citing works

Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species

Colloca, S., Barnes, E. J., Folgori, A., Ammendola, V., Capone, S., Cirillo, A., Siani, L., Naddeo, M., Grazioli, F., Esposito, M. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002925 · Cited by 299 · see citing works

Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate

Almazán, F., DeDiego, M. L., Sola, I., Zúñiga, S., Nieto-Torres, J. L., Márquez-Jurado, S., Andrés, G., & Enjuanes, L. (2013) · mBio · doi:10.1128/mbio.00650-13 · Cited by 285 · see citing works

Surveillance of Bat Coronaviruses in Kenya Identifies Relatives of Human Coronaviruses NL63 and 229E and Their Recombination History

Tao, Y., Shī, M., Chommanard, C., Queen, K. J., Zhang, J., Markotter, W., Kuzmin, I. V., Holmes, E. C., & Tong, S. (2017) · Journal of Virology · doi:10.1128/jvi.01953-16 · Cited by 266 · see citing works

Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations

Sánchez‐Ramón, S., Conejero, L., Netea, M. G., Sancho, D., Palomares, Ó., & Subiza, J. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02936 · Cited by 262 · see citing works

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 257 · see citing works

Immunosenescence: influenza vaccination and the elderly

Haq, K., & McElhaney, J. E. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.03.008 · Cited by 256 · see citing works

What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens?

Belyakov, I. M., & Ahlers, J. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901466 · Cited by 254 · see citing works

The Natural History and Transmission Potential of Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Châu, N. V. V., Lam, V. T., Dung, N. T., Yen, L. M., Minh, N. N. Q., Hung, L. M., Ngoc, N. M., Dung, N. T., Man, D. N. H., Nguyet, L. A., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa711 · Cited by 243 · see citing works

The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies

Mou, H., Raj, V. S., van Kuppeveld, F. J. M., Rottier, P. J. M., Haagmans, B. L., & Bosch, B. (2013) · Journal of Virology · doi:10.1128/jvi.01277-13 · Cited by 241 · see citing works

Non-specific effects of vaccines: Current evidence and potential implications

de Bree, L. C. J., Koeken, V. A. C. M., Joosten, L. A. B., Aaby, P., Benn, C. S., van Crevel, R., & Netea, M. G. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.06.002 · Cited by 233 · see citing works

T Cell–Mediated Host Immune Defenses in the Lung

Chen, K., & Kolls, J. K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100019 · Cited by 232 · see citing works

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Folegatti, P. M., Bittaye, M., Flaxman, A. L., Lopez, F. R., Bellamy, D. G., Kupke, A., Mair, C., Makinson, R., Sheridan, J., Rohde, C., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30160-2 · Cited by 230 · see citing works

Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2′-O-Methyltransferase Activity

Menachery, V. D., Yount, B. L., Josset, L., Gralinski, L. E., Scobey, T., Agnihothram, S., Katze, M. G., & Baric, R. S. (2014) · Journal of Virology · doi:10.1128/jvi.03571-13 · Cited by 213 · see citing works

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs

Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 212 · see citing works

Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro

Kam, Y., Kien, F., Roberts, A., Cheung, Y. C., Lamirande, E. W., Vogel, L., Chu, S. L., Tse, J., Guarner, J., Zaki, S. R., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.08.011 · Cited by 211 · see citing works

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

Ledgerwood, J. E., Costner, P. J. M., Desai, N., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.037 · Cited by 210 · see citing works

A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity

Smaill, F., Jeyanathan, M., Smieja, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006843 · Cited by 204 · see citing works

Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F., Wurie, A. H., Hou, L., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32617-4 · Cited by 200 · see citing works

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Vellozzi, C., Burwen, D. R., Dobardzic, A., Ball, R., Walton, K., & Haber, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.125 · Cited by 188 · see citing works

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

CZUB, M., WEINGARTL, H., CZUB, S., HE, R., & CAO, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.033 · Cited by 180 · see citing works

Virus-like particle vaccines: immunology and formulation for clinical translation

Donaldson, B., Lateef, Z., Walker, G. F., Young, S. L., & Ward, V. K. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1516552 · Cited by 180 · see citing works

Immune responses after live attenuated influenza vaccination

Mohn, K. G.-I., Smith, I., Sjursen, H., & Cox, R. J. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1377376 · Cited by 179 · see citing works

Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa

Xiang, Z., Li, Y., Cun, A., Yang, W. P., Ellenberg, S. S., Switzer, W. M., Kalish, M. L., & Ertl, H. C. J. (2006) · Emerging infectious diseases · doi:10.3201/eid1210.060078 · Cited by 178 · see citing works

Epitope‐based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study

Qamar, M. T. U., Saleem, S., Ashfaq, U. A., Bari, A., Anwar, F., & Alqahtani, S. M. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2116-8 · Cited by 178 · see citing works

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial

Satti, I., Meyer, J., Harris, S. A., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70845-x · Cited by 177 · see citing works

Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue

Aguiar, J. A., Tremblay, B. J.-M., Mansfield, M. J., Woody, O. Z., Lobb, B., Banerjee, A., Chandiramohan, A., Tiessen, N., Cao, Q., Dvorkin‐Gheva, A., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01123-2020 · Cited by 174 · see citing works

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)

Baden, L. R., Walsh, S. R., Seaman, M. S., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis670 · Cited by 166 · see citing works

T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

Arunachalam, P. S., Charles, T. P., Joag, V., Bollimpelli, V. S., Scott, M. K. D., Wimmers, F., Burton, S. L., LaBranche, C. C., Petitdemange, C., Gangadhara, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0858-8 · Cited by 165 · see citing works

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

Koch, T., Dahlke, C., Fathi, A., Kupke, A., Krähling, V., Okba, N. M. A., Halwe, S., Rohde, C., Eickmann, M., Volz, A., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30248-6 · Cited by 163 · see citing works

An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model

Chahal, J. S., Fang, T., Woodham, A. W., Khan, O. F., Ling, J. J., Anderson, D. G., & Ploegh, H. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-00193-w · Cited by 161 · see citing works

The Equitable Distribution of COVID-19 Therapeutics and Vaccines

Bollyky, T. J., Gostin, L. O., & Hamburg, M. A. (2020) · JAMA · doi:10.1001/jama.2020.6641 · Cited by 159 · see citing works

Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine

Jiménez-Guardeño, J. M., Regla-Nava, J. Á., Nieto-Torres, J. L., DeDiego, M. L., Castaño-Rodríguez, C., Fernández‐Delgado, R., Perlman, S. M., & Enjuanes, L. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005215 · Cited by 156 · see citing works

Understanding the T cell immune response in SARS coronavirus infection

Oh, H. J., Gan, S. K., Bertoletti, A., & Tan, Y. (2012) · Emerging Microbes & Infections · doi:10.1038/emi.2012.26 · Cited by 152 · see citing works

Novel viral vectors in infectious diseases

Humphreys, I. R., & Sebastian, S. (2017) · Immunology · doi:10.1111/imm.12829 · Cited by 148 · see citing works

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

Anywaine, Z., Whitworth, H. S., Kaleebu, P., PrayGod, G., Shukarev, G., Manno, D., Kapiga, S., Grosskurth, H., Kalluvya, S. E., Bockstal, V., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz070 · Cited by 146 · see citing works

From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza

Wood, J., & Robertson, J. S. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro979 · Cited by 140 · see citing works

Inactivated poliovirus vaccine: Past and present experience

Murdin, A. D., Barreto, L., & Plotkin, S. (1996) · Vaccine · doi:10.1016/0264-410x(95)00211-i · Cited by 135 · see citing works

Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease

Netland, J., DeDiego, M. L., Zhao, J., Fett, C., Álvarez, E. A., Nieto-Torres, J. L., Enjuanes, L., & Perlman, S. M. (2010) · Virology · doi:10.1016/j.virol.2010.01.004 · Cited by 134 · see citing works

Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay

Stephensen, C. B., Casebolt, D. B., & Gangopadhyay, N. N. (1999) · Virus Research · doi:10.1016/s0168-1702(99)00017-9 · Cited by 133 · see citing works

Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine

Iwata‐Yoshikawa, N., Uda, A., Suzuki, T., Tsunetsugu‐Yokota, Y., Sato, Y., Morikawa, S., Tashiro, M., Sata, T., Hasegawa, H., & Nagata, N. (2014) · Journal of Virology · doi:10.1128/jvi.00983-14 · Cited by 130 · see citing works

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity

Du, L., Zhao, G., Chan, C. C. S., Sun, S., Chen, M., Liu, Z., Guo, H., He, Y., Zhou, Y., Zheng, B., et al. (2009) · Virology · doi:10.1016/j.virol.2009.07.018 · Cited by 129 · see citing works

Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?

Sallenave, J., & Guillot, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01229 · Cited by 127 · see citing works

Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial Cells

Cardani, A. N., Boulton, A. M., Kim, T. S., & Braciale, T. J. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006140 · Cited by 127 · see citing works

Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice

Nakanaga, K., Yamanouchi, K., & FUJIWARA, K. (1986) · Journal of Virology · doi:10.1128/jvi.59.1.168-171.1986 · Cited by 126 · see citing works

Prospects for a MERS-CoV spike vaccine

Zhou, Y., Jiang, S., & Du, L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506702 · Cited by 125 · see citing works

Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures

Eroshenko, N., Gill, T., Keaveney, M. K., Church, G. M., Trevejo, J., & Rajaniemi, H. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0577-1 · Cited by 122 · see citing works

Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome

Lee, N. L. S., Chan, P. K. S., Ip, M., Wong, E., Ho, J., Ho, C., Cockram, C. S., & Hui, D. S. C. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2005.07.005 · Cited by 119 · see citing works

A human SARS-CoV neutralizing antibody against epitope on S2 protein

Duan, J., Yan, X., Guo, X., Cao, W., Han, W., Qi, C., Feng, J., Yang, D., Gao, G., & Jin, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.089 · Cited by 114 · see citing works

Rational Vaccine Design in the Time of COVID-19

Burton, D., & Walker, L. (2020) · Cell Host and Microbe · doi:10.1016/j.chom.2020.04.022 · Cited by 112 · see citing works

The Challenges of Vaccine Development against a New Virus during a Pandemic

Diamond, M., & Pierson, T. C. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.021 · Cited by 108 · see citing works

Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens

Afkhami, S., Yao, Y., & Xing, Z. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.30 · Cited by 108 · see citing works

Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?

Covián, C., Retamal-Díaz, A. R., Bueno, S. M., & Kalergis, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00970 · Cited by 104 · see citing works

Non-specific Effects of Vaccines Illustrated Through the BCG Example: From Observations to Demonstrations

Uthayakumar, D., Paris, S., Chapat, L., Freyburger, L., Poulet, H., & Luca, K. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02869 · Cited by 103 · see citing works

The search for a COVID-19 animal model

Lakdawala, S. S., & Menachery, V. D. (2020) · Science · doi:10.1126/science.abc6141 · Cited by 97 · see citing works

A Randomized, Controlled Trial of an Aerosolized Vaccine against Measles

Low, N. N., Bavdekar, A., Jeyaseelan, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407417 · Cited by 92 · see citing works

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults

Wilkie, M., Satti, I., Minhinnick, A., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.10.102 · Cited by 91 · see citing works

Distribution and storage of inflammatory memory in barrier tissues

Ordovas-Montañes, J., Beyaz, S., Rakoff-Nahoum, S., & Shalek, A. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-019-0263-z · Cited by 85 · see citing works

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens

Ewer, K., Sebastian, S., Spencer, A. J., Gilbert, S. C., Hill, A. V. S., & Lambe, T. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1383575 · Cited by 85 · see citing works

Innate immune memory of tissue-resident macrophages and trained innate immunity: Re-vamping vaccine concept and strategies

Xing, Z., Afkhami, S., Bavananthasivam, J., Fritz, D. K., D’Agostino, M. R., Vaseghi‐Shanjani, M., Yao, Y., & Jeyanathan, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr0220-446r · Cited by 85 · see citing works

Seroprevalence of neutralizing antibodies to human adenoviruses type‐5 and type‐26 and chimpanzee adenovirus type‐68 in healthy Chinese adults

Zhang, S., Huang, W., Zhou, X., Zhao, Q., Wang, Q., & Jia, B. (2013) · Journal of Medical Virology · doi:10.1002/jmv.23546 · Cited by 82 · see citing works

Early Clearance of Mycobacterium tuberculosis Is Associated With Increased Innate Immune Responses

Verrall, A. J., Schneider, M., Alisjahbana, B., Apriani, L., van Laarhoven, A., Koeken, V. A. C. M., van Dorp, S., Diadani, E., Utama, F., Hannaway, R. F., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz147 · Cited by 79 · see citing works

Pneumonia recovery reprograms the alveolar macrophage pool

Guillon, A., Arafa, E. I., Barker, K. A., Belkina, A. C., Martin, I. M. C., Shenoy, A. T., Wooten, A. K., Ana, C. L. D., Dai, A., Labadorf, A. T., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133042 · Cited by 76 · see citing works

Development of Live-Attenuated Arenavirus Vaccines Based on Codon Deoptimization

Cheng, B. Y. H., Ortiz-Riaño, E., Nogales, A., de la Torre, J. C., & Martínez‐Sobrido, L. (2015) · Journal of Virology · doi:10.1128/jvi.03401-14 · Cited by 74 · see citing works

Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV

Lokugamage, K. G., Iwata‐Yoshikawa, N., Ito, N., Watts, D. M., Wyde, P. R., Wang, N., Newman, P. C., Tseng, C.-T. K., Peters, C. J., & Makino, S. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.092 · Cited by 73 · see citing works

Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse®

Coughlin, M., Lou, G., Martinez, O., Masterman, S. K., Olsen, O. A., Moksa, A. A., Farzan, M., Babcook, J. S., & Prabhakar, B. S. (2007) · Virology · doi:10.1016/j.virol.2006.09.029 · Cited by 70 · see citing works

Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?

Moreno‐Fierros, L., García-Silva, I., & Rosales‐Mendoza, S. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1767062 · Cited by 69 · see citing works

Concurrent human antibody and T H 1 type T-cell responses elicited by a COVID-19 RNA vaccinePreprint

Şahin, U., Muik, A., Derhovanessian, E., et al. (2020) · medRxiv · doi:10.1101/2020.07.17.20140533 · Cited by 67 · see citing works

Deletion of both the Tyrosine-Based Endocytosis Signal and the Endoplasmic Reticulum Retrieval Signal in the Cytoplasmic Tail of Spike Protein Attenuates Porcine Epidemic Diarrhea Virus in Pigs

Hou, Y. J., Meulia, T., Gao, X., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01758-18 · Cited by 66 · see citing works

New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity

Jeyanathan, M., Yao, Y., Afkhami, S., Smaill, F., & Xing, Z. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.01.006 · Cited by 65 · see citing works

Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody

Lecomte, J., Cainelli‐Gebara, V. C. B., Mercier, G., et al. (1987) · Archives of Virology · doi:10.1007/bf01310740 · Cited by 65 · see citing works

The promise and challenge of epitope-focused vaccines

Oscherwitz, J. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1160977 · Cited by 62 · see citing works

Immune responses against severe acute respiratory syndrome coronavirus induced by virus‐like particles in mice

Lu, X., Chen, Y., Bai, B., Hu, H., Tao, L., Yang, J., Chen, J., Chen, Z., Hú, Z., & Wang, H. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02676.x · Cited by 61 · see citing works

Probability of symptoms and critical disease after SARS-CoV-2 infectionPreprint

Poletti, P., Tirani, M., Cereda, D., Trentini, F., Guzzetta, G., Sabatino, G., Marziano, V., Castrofino, A., Grosso, F., Del Castillo, G., et al. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2006.08471 · Cited by 60 · see citing works

A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates

Mueller, S., Stauft, C. B., Kalkeri, R., Koidei, F., Kushnir, A. S., Tasker, S. A., & Coleman, J. R. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.02.056 · Cited by 58 · see citing works

Mucosal adjuvants: Opportunities and challenges

Zeng, L. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1181236 · Cited by 54 · see citing works

Novel coronavirus-like particles targeting cells lining the respiratory tract

Naskalska, A., Dąbrowska, A., Nowak, P., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203489 · Cited by 42 · see citing works

Elicitation of Immunity in Mice After Immunization with the S2 Subunit of the Severe Acute Respiratory Syndrome Coronavirus

Guo, Y., Sun, S., Wang, K., Zhang, S., Zhu, W., & Chen, Z. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.510 · Cited by 38 · see citing works

Mucosal-Pull Induction of Lung-Resident Memory CD8 T Cells in Parenteral TB Vaccine-Primed Hosts Requires Cognate Antigens and CD4 T Cells

Haddadi, S., Vaseghi‐Shanjani, M., Yao, Y., Afkhami, S., D’Agostino, M. R., Zganiacz, A., Jeyanathan, M., & Xing, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02075 · Cited by 35 · see citing works

A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challengePreprint

Yahalom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E. B., Israeli, O., Milrot, E., Stein, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.18.160655 · Cited by 25 · see citing works

Top U.S. scientists left out of White House selection of COVID-19 vaccine short list

Cohen, J. D. (2020) · Science · doi:10.1126/science.abd1719 · Cited by 5 · see citing works

A guide to vaccinology: from basic principles to new developments

Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593 · see citing works

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., et al. (2021) · doi:10.1101/2021.08.18.21262237 · Cited by 543 · see citing works

COVID-19 vaccines: The status and perspectives in delivery points of view

Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375 · see citing works

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works

SARS-CoV-2 spreads through cell-to-cell transmission

Zeng, C., Evans, J. P., King, T., Zheng, Y.-M., Oltz, E. M., Whelan, S. P. J., Saif, L. J., Peeples, M. E., & Liu, S.-L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111400119 · Cited by 246 · see citing works

The known unknowns of T cell immunity to COVID-19

Karlsson, A. C., Humbert, M., & Buggert, M. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe8063 · Cited by 165 · see citing works

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models

Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Bonam, S. R., Zhong, C., Adam, A., Scharton, D., Rafael, G. H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq1945 · Cited by 122 · see citing works

Safety and efficacy of COVID‐19 vaccines: A systematic review and meta‐analysis of controlled and randomized clinical trials

Beladiya, J., Kumar, A., Vasava, Y., Parmar, K., Patel, D., Patel, S., Dholakia, S., Sheth, D., Boddu, S. H. S., & Patel, C. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2507 · Cited by 96 · see citing works

Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease

Case, J. B., Chen, R. E., Cao, L., Ying, B., Winkler, E. S., Johnson, M., Goreshnik, I., Pham, M. N., Shrihari, S., Kafai, N. M., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2021.06.008 · Cited by 73 · see citing works

Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2

Peng, L., Renauer, P. A., Ökten, A., Fang, Z., Park, J. J., Zhou, X., Lin, Q., Dong, M. B., Filler, R., Xiong, Q., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100634 · Cited by 21 · see citing works

Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

Li, C., Yu, D., Wu, X., Liang, H., Zhou, Z., Xie, Y., Li, T., Wu, J., Lu, F., Feng, L., et al. (2021) · doi:10.1101/2021.04.05.437224 · Cited by 73 · see citing works